NCT07672522 Exploratory Study on Infection and Immunosenescence Based on an Elderly Clinical Cohort
| NCT ID | NCT07672522 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huashan Hospital |
| Condition | Immunosenescence |
| Study Type | OBSERVATIONAL |
| Enrollment | 484 participants |
| Start Date | 2024-11-29 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 484 participants in total. It began in 2024-11-29 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational cohort study aims to investigate the relationship between immunosenescence and infectious diseases in older adults. Individuals aged 60 years and older, including elderly patients with infections and healthy controls, will be enrolled and followed longitudinally. Clinical information, laboratory test results, and health assessment data will be collected. Biological specimens, including peripheral blood, urine, stool, sputum, and nasopharyngeal swabs, will be obtained during enrollment and follow-up. Participants will undergo regular assessments of health status, infection events, and aging-related clinical characteristics. The study will evaluate age-related changes in immune function, immune cell composition, immune receptor repertoires, epigenetic characteristics, metabolic profiles, and respiratory and gut microbiota. By integrating clinical and multi-omics data, the study aims to identify biomarkers associated with immunosenescence, susceptibility to infection, disease severity, and clinical outcomes in older adults. The results are expected to improve understanding of the mechanisms linking aging, immune dysfunction, and infectious diseases, and to support the development of predictive models and preventive strategies for infection management and healthy aging in elderly populations.
Eligibility Criteria
Inclusion Criteria for the Healthy Control Group 1. No clinical symptoms suggestive of infection, including fever, cough, dyspnea, fatigue, or myalgia. 2. No abnormal physical signs, including lymphadenopathy, hepatomegaly, splenomegaly, or skin rash. 3. Normal laboratory test results, including complete blood count (CBC), C-reactive protein (CRP), and liver and renal function tests. 4. Healthy adults without underlying chronic diseases, no history of infectious diseases within the previous 6 months, and generally normal cognitive function. 5. Male or female. 6. Able to understand the study procedures and voluntarily provide written informed consent. Inclusion Criteria for the Infection Group 1.Age: 60 years or older; no gender restrictions. 2. Clinically diagnosed with an infectious disease by the treating physician. 3. The participant provides informed consent and signs the relevant documents. \-------------- Exclusion Criteria for the Healthy Control Group 1. Refusal to participate in the study; 2. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment. Exclusion Criteria for the Infection Group 1. Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, tumor, or other conditions). 2. Positive culture results are determined by the clinician to be due to colonization or contamination rather than infection. 3. Refusal to participate in the study. 4. Patients in critical or severe conditions who are unable to cooperate with sample collection. 5. Other conditions deemed unsuitable for inclusion as determined by the researchers.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07672522 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Immunosenescence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07672522 currently recruiting?
Yes, NCT07672522 is actively recruiting participants. Contact the research team at jingwenai1990@126.com for enrollment information.
Where is the NCT07672522 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07672522 clinical trial?
NCT07672522 is sponsored by Huashan Hospital. The trial plans to enroll 484 participants.